Boric acid’s cytotoxic effect on CD133+ cancer stem cells in H460 cell line

Basit Öğe Kaydı
dc.contributor.authorAcar, Muradiye
dc.date.accessioned2024-05-19T14:23:43Z
dc.date.available2024-05-19T14:23:43Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractAim: Cancer stem cells (CSCs) are found in a wide range of cancers, and CD133 is one of the most commonly used markers for detecting CSCs. Compared to CD133- populations in lung cancer, CD133+ cells are more capable of self-renewal, drug resistance and tumor initiation and demonstrate increased CSC capabilities. Though the anti-cancer activity of boric acid (BA) has been reported in relation to various cancers, there is no study showing its effect on CSCs. The aim of this study is to investigate the anti-cancer effects of BA in CD133+ CSCs and CD133- cells from lung cancer cells. Materials and Methods: The H460 lung carcinoma cell strain was obtained from the American Type Culture Collection. CD133+ CSCs and CD133- cells were separated using CD133 antibody conjugated to magnetic beads. The sphere formation assay (coated with SpheroMake) was used to assess the ability to maintain stemness. Cells were grown in serum-free RPMI1640 medium (with B27, N2 supplement, EGF and bFGF) to observe the development of spheres. To determine CD133 mRNA expression, total RNA was extracted and RT-qPCR was performed. The xCELLigence Real-Time Cellular Analysis (RTCA) system was used to determine the cytotoxic effects of BA. 25 mM, 12 mM, 6 mM, 3 mM, and 1 mM BA solutions were added to CD133+ CSCs and CD133- cells. Results: The CD133+ CSCs composed approximately 1% of H460 cells. The mRNA expression of CD133 was 16 times higher in CD133+ CSCs cells than in CD133- cells. CD133- cells failed to form spheres but CD133+ CSCs did so, demonstrating CD133+ CSCs stemness characteristics. The xCELLigence RTCA system determined the IC50 doses of BA to be 6.7 mM and 5 mM for CD133+ CSCs and CD133- cells. Conclusion: BA exhibited anti-cancer activity against the CD133+ CSCs and CD133- cells. This study is the first to demonstrate BA’s anti-cancer effect on CSCs.en_US
dc.identifier.doi10.5455/annalsmedres.2023.02.045
dc.identifier.endpage492en_US
dc.identifier.issn2636-7688
dc.identifier.issue4en_US
dc.identifier.startpage486en_US
dc.identifier.trdizinid1165300en_US
dc.identifier.urihttps://doi.org/10.5455/annalsmedres.2023.02.045
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1165300
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4099
dc.identifier.volume30en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.titleBoric acid’s cytotoxic effect on CD133+ cancer stem cells in H460 cell lineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu